Literature DB >> 30964169

MicroRNA-345 suppresses cell invasion and migration in non-small cell lung cancer by directly targeting YAP1.

M-Y Zhang1, J Lin, Y-C Kui.   

Abstract

OBJECTIVE: To investigate the roles and the underlying mechanism of miR-345 in regulating non-small cell lung cancer (NSCLC) cell migration and invasion. PATIENTS AND METHODS: Fifty-two pairs of NSCLC tissues and matched normal lung tissue samples were collected from NSCLC patients who had undergone surgical resection between June 2015 and August 2017 in our hospital. Human NSCLC cell lines (NCI-H460, NCI-H1299, A549 and GLC-82) and normal human bronchial epithelium cell BEAS-2B were cultured. NSCLC cell migration and invasion capacities were determined by transwell assays. The relative protein and mRNA expression level of yes-associated protein 1 (YAP1) were detected by Western blot and Quantitative Real-time polymerase chain reaction (qRT-PCR) analysis, respectively.
RESULTS: MiR-345 was prominently downregulated in NSCLC tissue specimens. Results of transwell assays showed that miR-345 overexpression could dramatically inhibit NSCLC cell migration and invasion. Additionally, data in current study also identified YAP1 as a direct functional target of miR-345 in NSCLC cells. YAP1 expressions were negatively correlated with the miR-345 expressions in NSCLC tissue samples. Moreover, YAP1 was found to be involved in the functions of miR-345 in inhibiting NSCLC cell invasion and migration.
CONCLUSIONS: All the above results indicated that miR-345 inhibited NSCLC cell migration and invasion by targeting YAP1, suggesting that miR-345/YAP1 axis might be a promising biomarker for NSCLC treatments.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30964169     DOI: 10.26355/eurrev_201903_17390

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  9 in total

Review 1.  The interplay between noncoding RNA and YAP/TAZ signaling in cancers: molecular functions and mechanisms.

Authors:  Yirao Zhang; Yang Wang; Hao Ji; Jie Ding; Keming Wang
Journal:  J Exp Clin Cancer Res       Date:  2022-06-14

2.  SARS-CoV-2 may regulate cellular responses through depletion of specific host miRNAs.

Authors:  Rafal Bartoszewski; Michal Dabrowski; Bogdan Jakiela; Sadis Matalon; Kevin S Harrod; Marek Sanak; James F Collawn
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-08-05       Impact factor: 5.464

3.  MicroRNA-877 inhibits cell proliferation and invasion in non-small cell lung cancer by directly targeting IGF-1R.

Authors:  Guohua Zhou; Jinglian Xie; Zikun Gao; Weishen Yao
Journal:  Exp Ther Med       Date:  2019-06-14       Impact factor: 2.751

4.  MicroRNA‑15a‑5p‑targeting oncogene YAP1 inhibits cell viability and induces cell apoptosis in cervical cancer cells.

Authors:  Xu Chen; Ruiqin Cao; Haifang Liu; Tuanying Zhang; Xinrong Yuan; Shuxiang Xu
Journal:  Int J Mol Med       Date:  2020-08-12       Impact factor: 4.101

5.  LncRNA NNT-AS1 promotes non-small cell lung cancer progression through regulating miR-22-3p/YAP1 axis.

Authors:  Wenlong He; Yeying Zhang; Shulan Xia
Journal:  Thorac Cancer       Date:  2020-01-10       Impact factor: 3.500

6.  MicroRNA‑199a‑3p inhibits ovarian cancer cell viability by targeting the oncogene YAP1.

Authors:  Yanfang He; Xiangyang Yu; Yajuan Tang; Yanjuan Guo; Jinling Yuan; Jinghe Bai; Tao Yao; Xiongzhi Wu
Journal:  Mol Med Rep       Date:  2021-02-04       Impact factor: 2.952

7.  miR‑29b promotes the osteogenic differentiation of mesenchymal stem cells derived from human adipose tissue via the PTEN/AKT/β‑catenin signaling pathway.

Authors:  Tian Xia; Shuanghai Dong; Jiwei Tian
Journal:  Int J Mol Med       Date:  2020-05-22       Impact factor: 4.101

8.  MicroRNA‑718 serves a tumor‑suppressive role in non‑small cell lung cancer by directly targeting CCNB1.

Authors:  Shu Wang; Hongmei Sun; Xiaokai Zhan; Qiwen Wang
Journal:  Int J Mol Med       Date:  2019-11-04       Impact factor: 4.101

Review 9.  Emerging Role of miR-345 and Its Effective Delivery as a Potential Therapeutic Candidate in Pancreatic Cancer and Other Cancers.

Authors:  Nagabhishek Sirpu Natesh; Brianna M White; Maia M C Bennett; Metin Uz; Rakhee Rathnam Kalari Kandy; Surinder K Batra; Surya K Mallapragada; Satyanarayana Rachagani
Journal:  Pharmaceutics       Date:  2021-11-23       Impact factor: 6.525

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.